Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06614309 · ClinicalTrials.gov registry record · NA
Non-invasive Treatment for Long COVID (Post COVID-19 Condition) Brain Fog
A NA study of Long COVID, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- NA
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT06614309: Recruiting NA study of Long COVID, sponsored by Mayo Clinic.
NCT06614309 is a NA study of Long COVID that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 45 participants, below the 2,187-participant average among 50 other Long COVID trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06614309, a NA study of Long COVID, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to assess the effects of both acute and chronic exposures to hypoxia and hypercapnia in patients with Long COVID syndrome.
Primary Outcome
The intracranial middle cerebral arteries will be obtained (MCAv) will be imaged with a linear probe and duplex ultrasound system to simultaneously measure CBFv by pulse wave doppler (peak and mean flow)
Conditions Studied
Interventions
- OTHER Acute Intermittent Hypoxia
- OTHER Acute Placebo Visit
- OTHER Acute Progressive Carbon Dioxide
- OTHER Training: Progressive Carbon Dioxide Ramping
- OTHER Training: Intermittent Hypoxic Exposure
Study Locations (1)
Arizona
- Mayo Clinic in Arizona - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2024-09-24 |
| Est. Completion | 2026-05 |
| Phase | NA |
What NCT06614309 shows while recruiting
NCT06614309 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 2,187-participant average among 50 other Long COVID trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Long COVID appearing as the primary indexed condition, and to 5 interventions - of which Acute Intermittent Hypoxia is the first listed.
NCT06614309 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT06614309 about?
NCT06614309 is a clinical study titled "Non-invasive Treatment for Long COVID (Post COVID-19 Condition) Brain Fog". This study aims to assess the effects of both acute and chronic exposures to hypoxia and hypercapnia in patients with Long COVID syndrome.
What is the current status of trial NCT06614309?
This trial is currently recruiting. It is a NA study. The enrollment target is 45 participants. The study started on 2024-09-24. Estimated completion is 2026-05.
What conditions does trial NCT06614309 study?
This clinical trial studies the following conditions: Long COVID.
What interventions are being tested in trial NCT06614309?
The interventions under investigation include: Acute Intermittent Hypoxia (OTHER), Acute Placebo Visit (OTHER), Acute Progressive Carbon Dioxide (OTHER), Training: Progressive Carbon Dioxide Ramping (OTHER), Training: Intermittent Hypoxic Exposure (OTHER).
Who is sponsoring clinical trial NCT06614309?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06614309 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Long COVID
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06614309's enrollment target sits among peer trials
45 36th of 50 higher than 15 of 50 other Long COVID trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Long COVID trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Water-based Activity to Enhance Recovery in Long COVID-19
RECRUITING · NA
-
Long-Covid-19 Alleviation Through Learning Mindfulness Study
RECRUITING · NA
-
Sauna for Long Covid
RECRUITING · NA
-
Long COVID Brain Fog: Cognitive Rehabilitation Trial
RECRUITING · NA
-
Heat thErapy And mobiLity in COVID-19 Survivors
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI